vs
CF BANKSHARES INC.（CFBK）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是CF BANKSHARES INC.的1.2倍（$19.6M vs $15.7M），CF BANKSHARES INC.净利率更高（40.0% vs -177.4%，领先217.5%），CF BANKSHARES INC.同比增速更快（12.6% vs -11.5%），CF BANKSHARES INC.自由现金流更多（$18.2M vs $-23.1M），过去两年CF BANKSHARES INC.的营收复合增速更高（13.7% vs -12.2%）
CF BANKSHARES INC.是一家美国区域性银行控股企业，通过旗下社区银行子公司运营，提供全方位个人及商业银行解决方案，包括存款产品、各类贷款、财富管理服务及数字银行工具，主要服务美国中西部地区的个人消费者和中小企客户。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CFBK vs LAB — 直观对比
营收规模更大
LAB
是对方的1.2倍
$15.7M
营收增速更快
CFBK
高出24.1%
-11.5%
净利率更高
CFBK
高出217.5%
-177.4%
自由现金流更多
CFBK
多$41.3M
$-23.1M
两年增速更快
CFBK
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $15.7M | $19.6M |
| 净利润 | $5.7M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | 43.4% | -168.5% |
| 净利率 | 40.0% | -177.4% |
| 营收同比 | 12.6% | -11.5% |
| 净利润同比 | 29.9% | -28.8% |
| 每股收益（稀释后） | $0.88 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CFBKLAB
| Q4 25 | $15.7M | — | ||
| Q3 25 | $15.5M | $19.6M | ||
| Q2 25 | $15.6M | $21.8M | ||
| Q1 25 | $14.1M | $40.8M | ||
| Q4 24 | $14.0M | — | ||
| Q3 24 | $13.1M | $22.1M | ||
| Q2 24 | $12.6M | $22.5M | ||
| Q1 24 | $12.2M | $45.5M |
净利润CFBKLAB
| Q4 25 | $5.7M | — | ||
| Q3 25 | $2.3M | $-34.7M | ||
| Q2 25 | $5.0M | $-33.5M | ||
| Q1 25 | $4.4M | $-26.0M | ||
| Q4 24 | $4.4M | — | ||
| Q3 24 | $4.2M | $-26.9M | ||
| Q2 24 | $1.7M | $-45.7M | ||
| Q1 24 | $3.1M | $-32.2M |
毛利率CFBKLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率CFBKLAB
| Q4 25 | 43.4% | — | ||
| Q3 25 | 17.5% | -168.5% | ||
| Q2 25 | 41.1% | -118.1% | ||
| Q1 25 | 39.5% | -80.8% | ||
| Q4 24 | 36.9% | — | ||
| Q3 24 | 40.4% | -120.9% | ||
| Q2 24 | 15.4% | -134.5% | ||
| Q1 24 | 30.9% | -132.2% |
净利率CFBKLAB
| Q4 25 | 40.0% | — | ||
| Q3 25 | 15.1% | -177.4% | ||
| Q2 25 | 32.3% | -153.7% | ||
| Q1 25 | 31.4% | -63.8% | ||
| Q4 24 | 35.2% | — | ||
| Q3 24 | 32.2% | -122.0% | ||
| Q2 24 | 13.5% | -203.3% | ||
| Q1 24 | 25.2% | -70.6% |
每股收益（稀释后）CFBKLAB
| Q4 25 | $0.88 | — | ||
| Q3 25 | $0.36 | $-0.09 | ||
| Q2 25 | $0.77 | $-0.09 | ||
| Q1 25 | $0.68 | $-0.07 | ||
| Q4 24 | $0.68 | — | ||
| Q3 24 | $0.65 | $-0.07 | ||
| Q2 24 | $0.26 | $-0.12 | ||
| Q1 24 | $0.47 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $184.4M | $399.7M |
| 总资产 | $2.1B | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CFBKLAB
| Q4 25 | $259.0M | — | ||
| Q3 25 | $272.4M | $129.4M | ||
| Q2 25 | $275.7M | $158.6M | ||
| Q1 25 | $241.0M | $150.9M | ||
| Q4 24 | $235.3M | — | ||
| Q3 24 | $233.5M | $210.6M | ||
| Q2 24 | $241.8M | $269.8M | ||
| Q1 24 | $236.9M | $287.1M |
总债务CFBKLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益CFBKLAB
| Q4 25 | $184.4M | — | ||
| Q3 25 | $179.3M | $399.7M | ||
| Q2 25 | $177.0M | $424.5M | ||
| Q1 25 | $172.7M | $454.6M | ||
| Q4 24 | $168.4M | — | ||
| Q3 24 | $164.0M | $489.3M | ||
| Q2 24 | $159.6M | $510.3M | ||
| Q1 24 | $158.0M | $577.3M |
总资产CFBKLAB
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | $539.6M | ||
| Q2 25 | $2.1B | $557.0M | ||
| Q1 25 | $2.1B | $579.6M | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | $681.5M | ||
| Q2 24 | $2.0B | $708.7M | ||
| Q1 24 | $2.0B | $777.7M |
负债/权益比CFBKLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.7M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $18.2M | $-23.1M |
| 自由现金流率自由现金流/营收 | 115.6% | -118.1% |
| 资本支出强度资本支出/营收 | 3.1% | 4.5% |
| 现金转化率经营现金流/净利润 | 3.26× | — |
| 过去12个月自由现金流最近4个季度 | $33.4M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流CFBKLAB
| Q4 25 | $18.7M | — | ||
| Q3 25 | $5.5M | $-22.2M | ||
| Q2 25 | $8.0M | $-20.7M | ||
| Q1 25 | $2.2M | $-30.3M | ||
| Q4 24 | $14.2M | — | ||
| Q3 24 | $-1.3M | $-27.9M | ||
| Q2 24 | $4.0M | $-39.0M | ||
| Q1 24 | $-1.2M | $-62.5M |
自由现金流CFBKLAB
| Q4 25 | $18.2M | — | ||
| Q3 25 | $5.2M | $-23.1M | ||
| Q2 25 | $7.8M | $-22.6M | ||
| Q1 25 | $2.2M | $-35.3M | ||
| Q4 24 | $13.9M | — | ||
| Q3 24 | $-1.3M | $-30.1M | ||
| Q2 24 | $4.0M | $-41.0M | ||
| Q1 24 | $-1.2M | $-63.3M |
自由现金流率CFBKLAB
| Q4 25 | 115.6% | — | ||
| Q3 25 | 33.6% | -118.1% | ||
| Q2 25 | 50.3% | -103.6% | ||
| Q1 25 | 15.2% | -86.6% | ||
| Q4 24 | 99.6% | — | ||
| Q3 24 | -9.9% | -136.4% | ||
| Q2 24 | 31.6% | -182.2% | ||
| Q1 24 | -9.5% | -138.9% |
资本支出强度CFBKLAB
| Q4 25 | 3.1% | — | ||
| Q3 25 | 1.7% | 4.5% | ||
| Q2 25 | 0.7% | 8.7% | ||
| Q1 25 | 0.4% | 12.4% | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 0.2% | 10.2% | ||
| Q2 24 | 0.1% | 8.6% | ||
| Q1 24 | 0.0% | 1.7% |
现金转化率CFBKLAB
| Q4 25 | 3.26× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 3.21× | — | ||
| Q3 24 | -0.30× | — | ||
| Q2 24 | 2.35× | — | ||
| Q1 24 | -0.38× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CFBK
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
